Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
IPO Date: October 1, 2002
Sector: Healthcare
Industry: Biotech
Market Cap: $81.01M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.14 | 3.86%
Avg Daily Range (30 D): $0.05 | 3.53%
Avg Daily Range (90 D): $0.05 | 3.57%
Institutional Daily Volume
Avg Daily Volume: .32M
Avg Daily Volume (30 D): .14M
Avg Daily Volume (90 D): .18M
Trade Size
Avg Trade Size (Sh.): 259
Avg Trade Size (Sh.) (30 D): 158
Avg Trade Size (Sh.) (90 D): 168
Institutional Trades
Total Inst.Trades: 47
Avg Inst. Trade: $1.96M
Avg Inst. Trade (30 D): $.8M
Avg Inst. Trade (90 D): $.92M
Avg Inst. Trade Volume: .39M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.96M
Avg Closing Trade (30 D): $1.04M
Avg Closing Trade (90 D): $1.04M
Avg Closing Volume: 917.3K
   
News
Jun 10, 2025 @ 12:56 PM
Galectin Therapeutics to Host Virtual KOL Event to...
Source: N/A
Jan 10, 2025 @ 1:00 PM
Galectin Therapeutics to Present at the 2025 MASH-...
Source: N/A
Aug 13, 2024 @ 12:00 PM
Galectin Therapeutics Reports Financial Results fo...
Source: N/A
Jun 4, 2024 @ 12:00 PM
Galectin Therapeutics to Present at the European A...
Source: Galectin Therapeutics Inc.
May 15, 2024 @ 12:00 PM
Galectin Therapeutics Reports Financial Results fo...
Source: Galectin Therapeutics Inc.
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-.72 $-.15 $-.19
Diluted EPS $-.72 $-.15 $-.19
Revenue $ M $ M $ M
Gross Profit $ $ $
Net Income / Loss $ -45.19M $ -9.63M $ -11.97M
Operating Income / Loss $ -40.68M $ -7.9M $ -12.43M
Cost of Revenue $ $ $
Net Cash Flow $ -7.69M $ -7.69M $ M
PE Ratio    
Splits
Mar 23, 2012:   1:6